MediWoundMDWD
About: MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
Employees: 111
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
350% more call options, than puts
Call options by funds: $306K | Put options by funds: $68K
39% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 18
11% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 9
0% more funds holding
Funds holding: 64 [Q4 2024] → 64 (+0) [Q1 2025]
2.95% less ownership
Funds ownership: 41.09% [Q4 2024] → 38.13% (-2.95%) [Q1 2025]
16% less capital invested
Capital invested by funds: $79M [Q4 2024] → $66.6M (-$12.4M) [Q1 2025]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 1 (-1) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Swayampakula Ramakanth | 66%upside $31 | Buy Maintained | 22 May 2025 |
Financial journalist opinion
